B20The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
Cora, N S, Sergio, B, Ugo, D G, Giuseppe, P, Simon, C, Wassim, A, Jose Angel, A A, Gedske, D, Karim, F, Eliahu, G, Axel, H, Florence, J, Ray, M, Axel, S M, Josep Maria, P, Brieuc, S, Srikala, S, Tony,Volume:
28
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdx423.019
Date:
October, 2017
File:
PDF, 56 KB
english, 2017